Viewing negative mentions of gene expression of Mhc (D. melanogaster) in T cells

Full-text article links are indicated by after the article reference.

Document Target Regulator Anatomy Sentence
Remedi et al. (2003)MHCT lymphocytesTumor cells cannot activate T lymphocytes, since they do not usually express major histocompatibility complex (MHC) class II molecules.
Pfeifer et al. (1993)MHCT-cellMost studies of exogenous antigen processing have used soluble antigens, which are not efficiently presented by class I MHC molecules and do not elicit CD8 T-cell responses in vivo.
Markmann et al. (1994)MHCT-cellUsing in vitro assays of T-cell function, we demonstrated that rats that rejected grafts lacking MHC expression evidenced sensitization of T cells specific for graft antigens presented by rat antigen-presenting cells.
Rodriguez-Barbosa et al. (2002)MHCT cellsThese observations would suggest that T cells selected on porcine thymic MHC would die rapidly in the periphery, where porcine MHC is absent.
Kimoto and Fathman (1981)MHCT cellUsing murine (T,G)-A--L-reactive T cell clones, we have demonstrated the existence of unique homozygous antigen-presenting determinants expressed on C57bl/6 mice, controlled by the I-A subregion of the murine major histocompatibility complex (MHC), which are not expressed on semisyngeneic (C57Bl/6 x A/J)F1 [(B6A)F1] cells.
Dick and Reske-Kunz (1989)MHCT-cellThese T cells do not express major histocompatibility complex (MHC) class II molecules on the cell surface as assessed on the basis of several criteria: by cytofluorometric analysis I-A and I-E determinants were not detectable; 10BK.1 cells could not act as antigen-presenting cells for long-term-cultured MHC class II-restricted T-cell clones; and monoclonal antibodies directed at both MHC class II isotypic complexes (I-A, I-E) did not suppress their OVA-induced activation.
Chitilian and Auchincloss (1997)MHCT cellClass II MHC-deficient animals have no detectable expression of class II MHC molecules and a reduction in the CD4+ T cell population.
Cohen et al. (2000)MHCT cellsOptimally prepared, adoptively transferred CD4+ T cells can reject established tumors with great efficiency even when targeted tumor cells express no MHC Class II molecules, implying that recognition of tumor antigen (Ag) occurs via MHC Class II-expressing host antigen-presenting cells (APC) within the tumor.
Wucherpfennig (1994)MHCT cellsNeuronal and myelin antigens are hidden from T cells as neurons and oligodendrocytes do not express MHC molecules.
Takada and Jameson (2009)MHCT cellIn this study, we explored naive CD8 T cell survival and function in nonlymphopenic conditions by using bone marrow chimeric donors and hosts in which class I MHC expression is absent or limited to radiosensitive versus radioresistant cells.
Dushek et al. (2009)pMHCT cellsThe observation that T cells transiently interact with APCs that do not express specific pMHC suggests that the decision to respond occurs within seconds of an encounter.
Schurmans et al. (2001)MHCT cellTumor rejection has all the characteristics of a CD8(+) T cell-mediated immune response, as the tumor did not express MHC class II and only tumor tissue was the subject of destruction.
Glas et al. (1994)MHCT cellBeta 2-Microglobulin-deficient (beta 2m -/-) mice are reported to lack cell surface expression of major histocompatibility complex (MHC) class I molecules, CD8+ T cells, and the ability to mount MHC class I-specific T cell responses.
Kerkhoff et al. (1993)MHCT cellsT cells were negative for CD25, CD54 and major histocompatibility complex (MHC)-class II.
Hardardottir et al. (1995)MHCT cellsWe find that T cells developing in mice that do not express the major histocompatibility complex (MHC) molecule recognized as self by the transgene-encoded TCR express both this TCR and a second TCR that is specific for the MHC molecules of the strain in which it arose.
Perez-Diez et al. (2007)MHCT cellsIn this mouse study, we compared monoclonal populations of tumor-specific CD4 and CD8 T cells as effectors against several different tumors, and found that CD4 T cells eliminated tumors that were resistant to CD8-mediated rejection, even in cases where the tumors expressed major histocompatibility complex (MHC) class I molecules but not MHC class II.
Kishimoto et al. (2004)MHCT cellsIn addition, to examine the role of indirect antigen presentation in the effect of DST, experiments used recipient mice that do not express MHC class II molecules on peripheral antigen-presenting cells, but do have functional CD4(+) T cells (II(-)4(+)).
Muller et al. (1992)MHCT cellsIntracranial infection of normal mice with lymphocytic choriomeningitis virus (LCMV) causes meningitis and death mediated by CD8+ major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTLs). beta 2-Microglobulin-deficient mice (beta 2M-/-) do not express functional MHC class I proteins and do not produce significant numbers of CD8+ T cells.
Smith and Roberts-Thomson (1990)MHCT lymphocytesSynovial fluid T lymphocytes contain a subpopulation of larger cells expressing MHC class II and other lymphocyte activation antigens with the exception of the IL2r.
Jiang and Chess (2000)MHCT cellsThe Qa-1 molecule may be uniquely qualified to serve this MHC restrictive function because, unlike conventional MHC molecules, it is preferentially and transiently expressed on activated and not resting CD4(+) T cells.
Mahnke et al. (2005)MHCT cellsIn contrast, such Ag-specific memory CD8(+) T cells were not detectable by peptide-major histocompatibility complex (MHC) multimer staining in animals that had not previously received an antigenic challenge.
Homma et al. (2005)MHCT cellsSplenic CD4+ T cells and CD8+ T cells from DC/BNL-treated mice showed cytotoxic activity against BNL cells after 3 days of incubation with DC/BNL, although BNL cells do not express major histocompatibility complex (MHC) class II molecules even after treatment with interferon (INF)-gamma.
Blish et al. (1999)MHCT cellsSecond, mature CD8+V beta 5+ T cells transit through a CD8lowV beta 5low deletional intermediate during tolerance induction by a process that depends upon neither mouse mammary tumor virus-encoded superantigens nor MHC class II expression.
Dembic et al. (2004)MHCT cellsWe have previously shown that tumour-specific CD4+ T cells protect against subcutaneous injections of major histocompatibility complex (MHC) class II-negative MOPC315 myeloma cells.
Bachmaier et al. (1997)MHCT cellsHowever, heart interstitial cells failed to express major histocompatibility complex (MHC) class II molecules in TNF-Rp55-/- animals, and adoptive transfer of autoreactive T cells resulted in heart disease only in TNF-Rp55-/- but not in TNF-Rp55-/- littermates.
Rovira et al. (1999)MHCT cellsRemarkably, in the absence of MHC molecules, UDA could not be efficiently presented to T cells by other glycosylated proteins.
Reilly et al. (2000)MHCT cellsMouse mammary tumor virus (MMTV) superantigens (vSAgs) can undergo intercellular transfer in vivo and in vitro such that a vSAg can be presented to T cells by major histocompatibility complex (MHC) class II proteins on antigen-presenting cells (APCs) that do not express the superantigen.
Halachmi et al. (1992)MHCT cellThe detachment and lytic activities of the MBP-reactive T cell lines tested were often independent of the presence of specific antigen, and were not restricted to syngeneic major histocompatibility (MHC) antigens.
Graber et al. (2008)MHCT cellsCD4 T cells are typically restricted to MHC class II which is not normally expressed on oligodendrocytes, the cell type that expressed MOG.
Pyrah and Watt (1996)MHCT cellsThere were no significant differences in the densities of CD8+, gamma/delta T cells, macrophages, B cells and MHC class H-expressing cells.
Gao et al. (2008)MHCT cellsNOD-b2m null mice do not express cell surface MHC class I molecules or produce detectable levels of CD8+ T cells and are diabetes and insulitis resistant [21].
Xie et al. (2010)MHCT cellsHowever, isolation of tumor-specific CD4+ T cells has been difficult (Wang, 2001) and only a few MHC class II vaccines have been produced as a result of the lack of knowledge of how to generate vaccines that specifically activate Th cells instead of tumor-specific Foxp3+ T reg cells (Rosenberg, 2001; Vence et al., 2007).